A Study of YL202 in Selected Patients With Advanced Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: NSCLC|Breast Cancer|HNSCC|Locally Advanced or Metastatic Solid Tumors
Interventions: DRUG: YL202 should be intravenously infused
Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.